menu
    • menu
    [{"orgOrder":0,"company":"Gebro Pharma","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Immunology","graph2":"Phase I","graph3":"Gebro Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Gebro Pharma \/ Gebro Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Gebro Pharma \/ Gebro Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Gebro Pharma

    Menu

    Gebro Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gebro Pharma

                            Austria arrow
                            FNCE
                            Not Confirmed

                            Gebro Pharma

                            Austria arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CID-103

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : CASI Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CASI Pharmaceuticals Plans IND Submission for CID-103 and Receives Acquisition Proposal

                            Details : CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody, being investigated for the treatment of antibody-mediated rejection ("AMR") in kidney transplant.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 26, 2024

                            Lead Product(s) : CID-103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : CASI Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth